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online-only Data Supplement. Out of the 23% of those excluded where full data sets were not available, there were a significantly higher rate of hemorrhagic stroke (17.3% versus 7.8%) and fewer lacunar strokes (14.6% versus 25.9%). Table 1 compares the crude rates for inpatient and early (within 7-day) mortality for each score point between the validation and derivation studies ( Figure I in the onlineonly Data Supplement). No statistically significant differences were observed in mortality rates between the studies for each score value for both outcomes. The sensitivities, specificities, positive and negative predictive values in predicting study mortality outcomes are shown in Table 2 for each cut-off value of SOAR score. The best balance of predictive value was observed for the cut-off score of 3 (ie, ≥3). The area under the receiver operator curves for inpatient mortality and 7-day mortality were 0.80 (95% confidence interval, 0.78-0.82) and 0.82 (95% confidence interval, 0.79-0.84), respectively.
Discussion
This external validation study suggests that the SOAR stroke score may help in predicting inpatient and 7-day mortality after acute stroke. In contrast to previously proposed stroke prognostic scores, SOAR contains only 4 easily obtainable variables. Furthermore, unlike other scores which cannot be used for both ischemic and hemorrhagic stroke, SOAR can be applied to both (Tables III and IV Approximately 76% and 64% of patients scoring 6 points died as inpatient in the derivation and validation studies, respectively (Table 1) . Thus, should a patient deteriorate rapidly, consideration of the initial SOAR score might support future management decisions. Further studies should compare the value of the SOAR score with clinical judgment and test the usefulness of well-defined treatment pathways for severe stroke.
The score can be calculated by both clinical and nonclinical staff (for administrative purposes) once the clinical assessment has been made, all 4 factors being fixed at time of evaluation. In addition, we used the data from 8 hospitals in the United Kingdom which would capture variations in stroke services 6 making the results more likely to be generalizable.
Our study has limitations. First, the score was only validated using hospital-based data. Second, differences were observed in hemorrhage rates, age, and prestroke Rankin between included and excluded patients. However, the internal relationship between the score and outcomes examined would not have been affected. A further potential limitation is the possibility of inter-rater variability and thus score reliability (eg, modified Rankin Scale). 7 However, the prestroke modified 
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Rankin scale was categorized into 0 to 2, 3 to 4, and 5, thus minimizing the impact of inter-rater variability. Although the sensitivity and specificity of the SOAR score are reasonable when cut-off point ≥3 is used, the positive predictive value was less impressive (only 23% with a SOAR score of 3 died) and this may result in some patients being assigned a misleading prognosis. As a result, clinical judgment still has a role in prognostication as the score has yet to be tested against clinical judgment. In summary, we found that the SOAR stroke score could predict inpatient and 7-day mortality in acute stroke; however, care must be taken in interpreting these results in view of the relatively low positive predictive values of the score. It is, however, simple to administer and can be implemented at time of admission. Future studies should evaluate if the score has value in predicting stroke mortality in different populations along with the ability to predict physical or cognitive function, discharge destination, and long-term mortality.
